Scholarlink

Introduction <p>The study objective was to describe characteristics and utilization patterns of tirzepatide users with type&#xa0;2 diabetes (T2D) using the Healthcare Integrated Research Database in the USA.</p> Methods <p>Adults (≥18&#xa0;years) included had T2D diagnosis; ≥1 tirzepatide claim (May&#xa0;2022–January 2023; first claim date = index date); and continuous medical and pharmacy enrollment during the 6-month baseline and follow-up periods from the index date. Baseline demographics, clinical characteristics, and 6-month follow-up dosing and treatment patterns were summarized descriptively.</p> Results <p>The study included 15,665 patients with T2D initiating tirzepatide (mean age: 53.2&#xa0;years; 58.5% women; 76.7% non-Hispanic white). During the 6-month baseline period, hypertension (69.2%), dyslipidemia (69.2%), overweight/obesity (58.4%), and obstructive sleep apnea (22.8%) were commonly reported comorbidities. Over half of the patients (51.2%) had used glucagon-like peptide-1 (GLP-1) receptor agonist (RA) before initiating tirzepatide. The mean glycated hemoglobin (HbA1c) was 7.6% (<i>n</i> = 5175), and 58.4% of these patients had HbA1c ≥7%. The mean body mass index (BMI) was 38.7&#xa0;kg/m<sup>2</sup> (<i>n</i> = 3459), and 87.8% of these patients either had Class&#xa0;1, 2, or 3 obesity. Among patients with a single prescription on each fill date (<i>N</i> = 14,986), 84.1% initiated tirzepatide at ≤5&#xa0;mg dose. During sixth prescription refill (<i>n</i> = 7304), 56.5% were receiving tirzepatide doses of &lt;10&#xa0;mg. During the 6-month follow-up period, 69.6% of patients had ≥1 dose escalation and 17.2% had ≥1 dose de-escalation. The mean time to first dose escalation was 59.1&#xa0;days and first dose de-escalation was 104.8&#xa0;days. Tirzepatide adherence (proportion of days covered [PDC] ≥80%) was 57.5% and persistence (45-day gap) was 73.3% at 6&#xa0;months. Of patients who discontinued tirzepatide (<i>n</i> = 4177; 26.7%), 29.1% re-initiated tirzepatide (45-day gap).</p> Conclusion <p>Patients with T2D initiating tirzepatide had multimorbidity; uncontrolled diabetes; and mean BMI was consistent with Class&#xa0;2 obesity. Patients showed favorable tirzepatide adherence and persistence profiles, and the majority remained at &lt;10&#xa0;mg doses during the 6-month follow-up period.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月10日

查看全文
  • Reema Mody,
  • Karishma Desai,
  • Chia-Chen Teng,
  • Gally Reznor,
  • Grace Stockbower,
  • Michael Grabner,
  • Brian D. Benneyworth

摘要

Introduction

The study objective was to describe characteristics and utilization patterns of tirzepatide users with type 2 diabetes (T2D) using the Healthcare Integrated Research Database in the USA.

Methods

Adults (≥18 years) included had T2D diagnosis; ≥1 tirzepatide claim (May 2022–January 2023; first claim date = index date); and continuous medical and pharmacy enrollment during the 6-month baseline and follow-up periods from the index date. Baseline demographics, clinical characteristics, and 6-month follow-up dosing and treatment patterns were summarized descriptively.

Results

The study included 15,665 patients with T2D initiating tirzepatide (mean age: 53.2 years; 58.5% women; 76.7% non-Hispanic white). During the 6-month baseline period, hypertension (69.2%), dyslipidemia (69.2%), overweight/obesity (58.4%), and obstructive sleep apnea (22.8%) were commonly reported comorbidities. Over half of the patients (51.2%) had used glucagon-like peptide-1 (GLP-1) receptor agonist (RA) before initiating tirzepatide. The mean glycated hemoglobin (HbA1c) was 7.6% (n = 5175), and 58.4% of these patients had HbA1c ≥7%. The mean body mass index (BMI) was 38.7 kg/m2 (n = 3459), and 87.8% of these patients either had Class 1, 2, or 3 obesity. Among patients with a single prescription on each fill date (N = 14,986), 84.1% initiated tirzepatide at ≤5 mg dose. During sixth prescription refill (n = 7304), 56.5% were receiving tirzepatide doses of <10 mg. During the 6-month follow-up period, 69.6% of patients had ≥1 dose escalation and 17.2% had ≥1 dose de-escalation. The mean time to first dose escalation was 59.1 days and first dose de-escalation was 104.8 days. Tirzepatide adherence (proportion of days covered [PDC] ≥80%) was 57.5% and persistence (45-day gap) was 73.3% at 6 months. Of patients who discontinued tirzepatide (n = 4177; 26.7%), 29.1% re-initiated tirzepatide (45-day gap).

Conclusion

Patients with T2D initiating tirzepatide had multimorbidity; uncontrolled diabetes; and mean BMI was consistent with Class 2 obesity. Patients showed favorable tirzepatide adherence and persistence profiles, and the majority remained at <10 mg doses during the 6-month follow-up period.